[New oral anticoagulant pharmacology]

All new oral anticoagulants are direct specific reversible inhibitors, either direct factor Xa inhibitors or inhibitors of thrombin. The pharmacokinetic of the new drugs is mediated by P- glycoprotein (P-gp) and metabolised by liver enzymes for some of them, principally cytochrome P450. That explains an important risk of drug interactions. The particularity of these new drugs is a priori a pharmacokinetic and pharmacodynamic profile more predictable involving no need for laboratory monitoring. In some clinical situations (risk of too high or too low exposure), a specific dose is proposed.